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An analysis of direct medical care cost differences be-
tween Alzheimer’s and non-Alzheimer’s patients enrolled
in a managed care organization (MCO) was conducted.
OBJECTIVE: The purpose of this study was to determine
a difference between direct medical costs of Alzheimer’s
patients and elderly non-Alzheimer’s patients.
METHODS: Direct medical costs were collected for a
1-year period for the MCOs Alzheimer’s population con-
sisting of 266 patients. Direct medical costs were also
collected for this period for the population of elderly
patients without a diagnosis of Alzheimer’s disease (AD)
(n  13,553). These costs did not include nursing home
or prescription costs. Medical costs from the population
databases were compared.
RESULTS: A greater proportion of AD patients were
hospitalized during the year (38.0% versus 16.3%) and
mean length of hospital stay was slightly longer for AD
patients (5.7 days versus 5.4 days). On a per patient ba-
sis, AD patients received more inpatient hospital services
(51.5 versus 43.3), outpatient hospital services (11.6 ver-
sus 10.6), and physician office services (15.8 versus 14.8)
than non-AD patients. As a proportion of total costs,
non-AD patients had a greater proportion associated
with outpatient services (67.9% versus 43.8%), whereas
AD patients had a higher proportion associated with in-
patient services (48.9% versus 30.2%). The mean cost
per person for services for AD patients was $4440.67
(sd  7148.14) compared to $2753.12 (sd  5465.61)
for non-AD patients, yielding a difference of $1687.55
per patient that may be attributed to AD.
CONCLUSION: The Alzheimer’s population of this
MCO utilized more services and had a higher mean an-
nual cost per person than the non-Alzheimer’s elderly
population.
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OBJECTIVES: To construct a disease-based simulation
model to estimate the clinical and economic outcomes of
treating bipolar disorder with mood stabilizers.
METHODS: Information obtained from the literature
and interviews with clinical psychiatrists were utilized to
develop a conceptual model of bipolar disorder and its
treatment. In a conceptual framework utilizing properties
of the Markov process, seven health states were identi-
fied. A treatment algorithm that captures modal prescrib-
ing patterns was developed to model the use of four
mood stabilizers, alone or in combination, and three cat-
egories of adjunctive agents, with mood stabilizer ther-
apy changing in response to transitions in health states.
Healthcare resources in the model include emergency de-
partment visits, hospitalization, office visits, laboratory
tests, procedures and drug therapy, with resource con-
sumption varying with mood stabilizer treatment and
health state.
RESULTS: A Monte Carlo computer simulation model
of bipolar disorder was developed. The simulation dura-
tion, cohort size and initial health state can be varied. All
base-case estimates can be modified to reflect a diversity
of clinical and economic data and practice patterns. Al-
ternative treatments and treatment algorithms can be in-
corporated. The simulation allows cycle length duration
to be varied for specific health states. Reports present
clinical and economic results for each simulation run.
CONCLUSIONS: Utilizing a discrete-state Monte Carlo
simulation, data from numerous sources can be combined
to estimate the clinical outcomes and economic conse-
quences of using one or more mood stabilizers in various
health states experienced by patients with bipolar disorder.
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OBJECTIVE: This study examined the medical utiliza-
tion and cost experiences of ambulatory Medicaid pa-
tients diagnosed with schizophrenia.
METHODS: A historical cohort design was used. Eligi-
ble patients between 18 and 65 years were assigned to
risperidone (N  1438), clozapine (N  845), haloperi-
dol (N  1029), or other conventional antipsychotic
(N  1503) drug cohorts based on type of antipsychotic
drug that was first used during a 1-year window of time.
Using an intent-to-treat approach, we report total and
schizophrenia-related hospital, emergent care, drug, out-
patient visit, laboratory use, and cost experience based
on paid claims data 6 months before and 12 months after
the index date. Multiple regression analyses were used to
determine the strength of the association of drug use with
costs of care, controlling for demographic characteristics
and baseline use of medical care services.
RESULTS: Medical care service use declined 20% or
more during the 12-month follow-up period. Schizophre-
nia-related costs comprised slightly over 70% of total
costs for patients in the clozapine cohort, and slightly
over 40% of total costs for the other cohorts. OLS re-
gression explained approximately 50% of the variance in
patient costs of care. Higher total and schizophrenia-
related costs were associated with cost of care during
baseline, clozapine use, risperidone use, number of
months of antipsychotic drug use, and comorbidities.
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CONCLUSION: There were considerable differences in
the use of medical services by patients with schizophre-
nia. Of the four cohorts examined, clozapine users had
the fewest hospitalizations at baseline and during the fol-
low-up period, but also the highest costs.
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Following recommended dosage and duration protocols
from the start of a treatment episode is essential to
achieving optimal clinical outcomes through pharmaco-
therapy. For retrospective claims database analysis of an-
tipsychotic medications, early refills and/or dose titration
can complicate comparisons of an individual patient’s
dose and duration pattern to recommended protocols.
OBJECTIVE: The objective was to determine whether an
algorithm adjusting for early refills and dose titrations in
antipsychotic claims resulted in significant changes.
METHODS: Antipsychotic prescriptions dispensed be-
tween October 1995 and December 1997 to 21,536 eligi-
ble subjects were extracted from a large US prescription
claims database. Patients starting a new episode—initia-
tors (n  3244)—received their initial antipsychotic med-
ication between October 1996 and December 1996, but
received no antipsychotic agents in the preceding 365
days. Antipsychotics dispensed within 365 days after the
initial agent were used to calculate mean daily dose and
duration for initiators by medication. Paired t tests as-
sessed differences between patient-level dose and dura-
tion measures calculated with and without the algorithm.
RESULTS: Use of the algorithm significantly reduced du-
ration and significantly raised mean daily doses for initia-
tors taking one of seven antipsychotic medications. For
three agents—olanzapine, risperidone, and thioridazine—
both dose and duration differences were significant at p 	
0.0001. Dosing and duration p-values, respectively, for the
other agents were: chlorpromazine (0.0024, 0.0329), halo-
peridol (0.0017, 0.0002), perphenazine (0.0101, 0.0003),
and trifluoperazine (0.0348, 0.0026).
CONCLUSIONS: Applying the algorithm resulted in sig-
nificant changes to antipsychotic dose and duration val-
ues. Therefore, before comparing patterns developed
from retrospective antipsychotic claims to recommended
guidelines, dose and duration must be adjusted to ac-
count for early refills and/or titration.
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OBJECTIVES: To investigate whether the association be-
tween higher healthcare costs and delays or changes in an-
tipsychotic drug therapy, which was found in previous
1-year period study, continue to accrue over a 2-year
period.
METHODS: For this study 1966 patients with schizo-
phrenia covered by the California Medicaid (Medi-Cal)
program were selected. Multiple logistic regression mod-
els were estimated for the likelihood of delaying therapy
and changing therapy and OLS regressions were used to
estimate the cost effects of these drug use patterns in both
1-year and 2-year models.
RESULTS: Of patients, 21.1% did not use an antipsy-
chotic medication in the first year and 17.6% were un-
treated for 2 years. As before, treated patients used sig-
nificantly less psychiatric hospital services over 2 years
($6906, p  0.0025), but more nursing home services
($7508, p  0.0074) and prescription drugs ($962,
p  0.0001). Nearly 28% of patients treated within 2
years delayed the onset of drug therapy more than 30
days. Having started a delayed course of antipsychotic
therapy during the first year was associated with signifi-
cantly higher first year total costs ($5223, p  0.0270).
However, this impact of delayed therapy measured over
2 years decreased to $2678 (p  0.5158). For patients
with no delay in the start of drug therapy, 48% change
therapy in the first year, which increases to nearly 55%
after 2 years. Patients who change drug therapy exhibit
significantly higher costs: $10,517 after 1 year and
$15,206 over 2 years.
CONCLUSIONS: As in the earlier analysis, antipsychotic
drug use patterns in Medi-Cal suggest that standard med-
ications do not meet the therapeutic needs of patients
with schizophrenia, which results in higher total health-
care costs.
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OBJECTIVE: The purpose of this present study was to
ascertain the economic burden due to the annual direct
costs of psychotropic medications used in the manage-
ment of psychiatric disorders in a developing country
with limited financial resources.
METHODS: The direct costs of the psychopharmacologi-
cal agents evaluated were: 1) antidepressants like tricyclic,
SSRI, and newer antidepressants available; 2) antipsychot-
ics like phenothiazines, butyrophenones, and atypical an-
tipsychotics; 3) benzodiazepines and sedatives. The annual
